GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeImmune Inc (OTCPK:GBIM) » Definitions » Forward Dividend Yield %

GlobeImmune (GlobeImmune) Forward Dividend Yield % : 0.00% (As of May. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is GlobeImmune Forward Dividend Yield %?

As of today (2024-05-21), the Forward Annual Dividend Yield of GlobeImmune is 0.00%.

As of today (2024-05-21), the Trailing Annual Dividend Yield of GlobeImmune is 0.00%.

GBIM's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.555
* Ranked among companies with meaningful Forward Dividend Yield % only.

GlobeImmune's Dividends per Share for the three months ended in Mar. 2016 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of GlobeImmune's Forward Dividend Yield %

For the Biotechnology subindustry, GlobeImmune's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeImmune's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeImmune's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where GlobeImmune's Forward Dividend Yield % falls into.



GlobeImmune Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


GlobeImmune  (OTCPK:GBIM) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


GlobeImmune Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of GlobeImmune's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeImmune (GlobeImmune) Business Description

Traded in Other Exchanges
N/A
Address
1450 Infinite Drive, Louisville, CO, USA, 80027
GlobeImmune Inc is a US-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.
Executives
Augustine Lawlor director 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Daniel J Mitchell director
S. Edward Torres director C/O LILLY VENTURES FUND I LLC, 115 W. WASHINGTON ST, STE 1680 SOUTH, INDIANAPOLIS IN 46204
Healthcare Ventures Vii Lp other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
John W Littlechild other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
James H Cavanaugh other: Former 10% Owner 265 HOTHORPE LANE, VILLANOVA PA 19085
Harold R Werner other: Former 10% Owner C/O HEALTHCARE VENTURES LLC, 44 NASSAU STREET, PRINCETON NJ 08542
Christopher Mirabelli other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Healthcare Partners Vii, L.p. other: Former 10% Owner 44 NASSAU STREET, PRINCETON NJ 08542
J William Freytag director
Rodell Timothy C Jr director, officer: CEO & Pres 201 MIDLAND AVE, ASPEN CO 81611
Celgene Corp /de/ 10 percent owner 86 MORRIS AVENUE, SUMMIT NJ 07901
Morgenthaler Partners Vii Lp 10 percent owner 50 PUBLIC SQUARE, SUITE 2700, CLEVELAND OH 44113

GlobeImmune (GlobeImmune) Headlines

No Headlines